Jim Simons' quantitative hedge fund, Renaissance Technologies, has liquidated its entire position in Bristol-Myers Squibb (BMY), according to a recent quarterly disclosure. The filing, which reflects holdings as of June 30, 2026, revealed the sale of all 977,050 shares, valued at approximately $59.26 million at the time of reporting. Investors should note that 13F filings are submitted to the SEC up to 45 days after a quarter ends, so these trades occurred between April and June.
The move is notable as Bristol-Myers Squibb was historically a significant holding for the fund. The exit precedes BMY's strong second-quarter financial report, where the company announced a 6% increase in revenue and raised its full-year guidance. No specific reason for the sale was disclosed by the famously secretive investment firm.